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Abstract
The underlying mechanisms resulting in the profound immune suppression characteristic of human visceral leishmaniasis
(VL) are not fully understood. Here, we tested the hypothesis that arginase, an enzyme associated with
immunosuppression, is higher in patients with VL and contributes to impaired T cell responses. We recruited patients
with VL before and after treatment and healthy controls and measured the arginase metabolism in the blood of these
individuals. Our results show that arginase activity is significantly higher in the blood of patients with active VL as compared
to controls. These high levels of arginase decline considerably once the patients are successfully treated. We identified the
phenotype of arginase-expressing cells among PBMCs as neutrophils and show that their frequency was increased in PBMCs
of patients before treatment; this coincides with reduced levels of L-arginine in the plasma and decreased expression levels
of CD3f in T cells.
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Introduction
Visceral leishmaniasis (VL) is a neglected tropical disease caused
by parasites of the Leishmania (L.) donovani complex. The incidence of
VL is estimated to be 500 000 cases every year, with approxi-
mately 50 000 deaths, predominantly in India, Bangladesh, Brazil,
Nepal and Sudan. It inflicts an immense toll on the developing
world and impedes economic development; it is the second biggest
parasitic killer in the world after malaria, with an estimated loss of
2.3 million disability-adjusted life years. There is no efficient
vaccine; currently used chemotherapy is toxic and increasing drug
resistance is reported [1]. VL can be asymptomatic or can
manifest as a progressive disease characterised by hepatospleno-
megaly, fever, weight loss, hyperglobulinemia and pancytopenia
[1]. In Ethiopia, VL is caused by L. donovani and it is one of the
most significant vector-borne diseases; Ethiopia has the second
largest number of VL cases in sub-Saharan Africa with an
estimated annual burden of 4500 to 5000 new cases [2]. Sodium
stibogluconate (SSG) is still the main drug used as first line of
treatment in Ethiopia [2] and a case fatality rate of 13% has been
reported [3]. VL is worsened by malnutrition and HIV co-
infection, and treatment access is often difficult because of the
remote location of areas endemic for VL.
Based on extensive studies in mouse models, healing of disease
and host protection against Leishmania infection is dependent on
the development of a T helper (Th)1 type response, characterised
by the production of IFN-c and nonhealing is associated with an
IL-4-dominated Th2 type response (reviewed in [4]). However,
concentrations of these two cytokines in plasma of symptomatic
patients with visceral leishmaniasis (VL patients) do not always
correlate with clinical outcome: studies have reported both an
increase [5,6,7,8] or decrease [9] in IFN-c levels during the active
phase of VL. Whereas IL-4 increases in plasma of VL patients in
some studies [8,9,10], it has also been shown to be below detection
limit in other cases [6,11]. In contrast, increased levels of IL-10, a
potent immunosuppressive cytokine, have consistently been
associated with symptomatic VL (reviewed in [12]), suggesting
that rather than a set Th1 or Th2 type response, IL-10 plays a
crucial role in chronic nonhealing/or symptomatic VL. Indeed,
one of the key immunological characteristics of active VL is a
profound immunosuppression, as demonstrated by the failure of
PBMCs to produce IFN-c and proliferate in response to Leishmania
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antigen; this impaired capacity to respond to antigenic challenge is
however restored following successful chemotherapy [6] and
reviewed in [12,13].
Arginase-induced L-arginine metabolism has been identified as
a potent mechanism of immune suppression [14,15,16]. We have
recently shown in an experimental model of cutaneous leishman-
iasis that high arginase activity, a hallmark of nonhealing disease,
is primarily expressed locally at the site of pathology. The high
arginase activity caused local depletion of L-arginine, which
impaired the capacity of CD4+ T cells in the lesion to proliferate
and to produce interferon-gamma, while T cells in the local
draining lymph nodes responded normally. Healing resulted in
control of arginase activity and reversal of local immunosuppres-
sion. Furthermore, inhibition of arginase as well as supplementa-
tion with L-arginine restored T cell effector functions and reduced
parasite growth at the site of lesions [17]. In addition, it has been
recently shown in a hamster model of visceral leishmaniasis that
increased arginase activity resulted in impaired control of infection
[18].
In the present study, we tested the hypothesis that during
human visceral leishmaniasis, arginase activity increases and
results in depletion of L-arginine.
Materials and Methods
Subjects and sample collection
The study was approved by the Ethiopian National Research
Ethics Review Committee (NRERC, reference 310/18/03), by
Addis Ababa University Medical Faculty Institutional Review
Board (IRB, reference 023/2009) and by the Joint UCL/UCLH
Committees on the Ethics of Human Research (Committee Alpha,
reference 09/H0715/93). For this study, 26 patients with visceral
leishmaniasis were recruited from the Leishmaniasis Treatment
and Research Center of Gondar University Hospital before
treatment. The exclusion criteria were age (,5), tuberculosis,
malaria, HIV and pregnancy; no women presented with visceral
leishmaniasis during our study, all patients were male migrant
workers. The diagnosis of VL was based on positive serology
(rK39) and presence of amastigotes in spleen or bone marrow
aspirates. Fourteen male healthy controls with no prior history of
VL were recruited among the staff (10 controls) in the clinic and
from the patients’ household contacts (4 controls). Informed
written consent was obtained from each patient or parent/
guardian and control. 10–20 ml of blood was collected in EDTA
tubes before the treatment started. All patients were treated with
20 mg/kg/day of SSG for 30 days and showed an initial clinical
cure rate of 100% after treatment. In addition there was no
significant treatment related adverse event.
A further 10 ml of blood was collected from 14 patients 21 to 28
days after treatment had started. Of note, in all the tests performed
in this study, no significant differences were obtained between
patients after 3 weeks of treatment as compared to 4 weeks of
treatment.
It was not possible to always analyse the samples from all
patients before and after treatment for two reasons: poor medical
conditions of the patients at arrival in the hospital and/or frequent
electricity cuts that did not allow for immediate processing of the
blood.
Plasma was isolated by centrifuging 1 ml of blood at 1800 rpm
for 10 min and was frozen at 220uC until further use. Peripheral
blood mononuclear cells (PBMCs) were isolated by density
gradient centrifugation on Histopaque-1077 (Sigma). Cells were
counted by trypan blue exclusion, washed in phosphate buffered
saline (PBS) and were used immediately for flow cytometry;
PBMCs used for arginase and protein determination were
immediately resuspended in lysis buffer (0.1% Triton X-100,
25 mM Tris-HCl and 10 mM MnCl2, Sigma) and frozen at
220uC until further use.
Laboratory evaluation
The following tests were used to diagnose the presence of HIV:
KHB Shanghai Kehua Bio-engineering Co. Ltd and Chembio
HIV 1/2 STAT-PAK; Uni-Gold (Trinity Biotech PLC) was used
to resolve ambiguous results.
CD4+ and CD8+ T cell counts were determined using a BD
Multi TEST kit (BD Biosciences) and acquisition was performed
using a FACSCalibur (BD Biosciences). Haematological data
(platelet counts, white blood cell counts, hematocrit and haemo-
globin) were obtained with a COULTER AcNT diff Hematology
Analyzer.
Determination of arginase activity
The enzymatic activity of arginase in PBMCs and in plasma
and protein concentration of PBMC samples was measured as
previously described [19].
HPLC quantification of L-arginine
L-arginine concentrations were determined in plasma obtained
from citrated blood either directly or after concentrating cationic
amino acids using Oasis MCX ion exchange columns (Waters,
Eschborn, Germany) as described before [20].
Flow cytometry
Antibodies used were as follows: anti-CD4 (clone 13B8.2,
Beckman Coulter), anti-CD8 (clone RPA-T8, BD Biosciences),
anti-CD3f (Santa Cruz: clone 6B10.2), anti-CD14 (BD Pharmin-
gen: cloneM5E2), anti-CD15 (Clone H198, BD Pharmingen) and
anti-CD63 (Beckman Coulter: CLBGran/12); anti-arginase I
(HyCult Biotechnology: clone 6G3) and the isotype control (BD
Pharmingen: clone MOPC21) were coupled with Alexa FluorR
488 (Molecular Probes). Cells were washed with PBS, the fixation
Author Summary
Leishmaniases, a group of diseases caused by a parasite,
Leishmania, belong to the most neglected tropical
diseases: they are mainly found in low-income countries
and affect the poorest populations. These parasites infect
cells of the immune system called macrophages, which
can kill the intracellular parasites when they receive the
right signals from other cells of the immune system, the
lymphocytes. During the active phase of visceral leish-
maniasis, it has been shown that lymphocytes lose their
capacity to instruct the macrophages to kill the intracel-
lular parasites. Here, we show that the levels of an enzyme,
arginase, are significantly increased in the blood of
patients with visceral leishmaniasis, but decrease to the
same levels as those of healthy controls following
successful treatment. Arginase has the capacity to deplete
an amino acid, L-arginine, which is crucial for the activation
of lymphocytes. Indeed, our results show that the levels of
this amino acid are considerably decreased in patients with
visceral leishmaniasis. Our results suggest that during the
active phase of visceral leishmaniasis, increased arginase
results in the depletion of L-arginine, which is responsible
for the incapacity of lymphocytes to send the adequate
signals to the macrophages.
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step was performed with 2% formaldehyde in PBS and the
permeabilisation step with 0.5% saponin in PBS.
The determination of intracellular arginase was performed as
described in [21]. The percentages for the isotype controls were
,1%. Acquisition was performed using a FACSCalibur (BD
Biosciences) and data were analyzed using Summit v4.3 software.
Statistical analysis
Data were evaluated for statistical differences using a two-tailed
Mann-Whitney test (GraphPad Prism 5) and differences were
considered statistically significant at p,0.05. Unless otherwise
specified, results are expressed as median6 SEM.
Results
Clinical data
All patients recruited in this study were male with a median age of
2261.1 years and presented with severe VL as shown by the clinical
data presented in Table 1: all but one patients had enlarged spleen
and/or liver and parasites were detected in the spleen or bone
marrow aspirates of all patients. As shown in Table 1, the duration
of illness varied from 2 to 24 weeks. In addition, the following
parameters were measured: platelet and white blood cell counts,
hematocrit and haemoglobin. Platelets and WBC counts were
noticeably lower than the normal range in the large majority of the
patients (Table 2). In addition, all but one patient had hematocrit
and haemoglobin levels below the lower limit of normal (Table 2).
The nutritional status of VL patients was determined by calculating
their body mass index (BMI) and their upper arm circumference:
the majority of the patients had a BMI below 18.5 (median6SEM:
16.560.3): out of 25 patients, 11 were malnourished [22]
(BMI,18.5) and 12 were severely malnourished [22] (BMI,16);
the BMI of all controls were above 18.5 (21.560.8) (Figure 1A). We
did not find a significant difference between the BMI of the 4
endemic controls and the 8 controls recruited among the staff of the
hospital (20.761.2 vs 22.460.7 respectively, p= 0.2828, data not
shown). The median arm circumference was also significantly lower
in VL patients (controls: 26.060.4 cm, patients: 21.060.8 cm,
p,0.0001, Figure 1B). CD4+ and CD8+ T cell counts were assessed
and results in Figures 1C and D show that they were markedly
reduced in the blood of VL patients (CD4+ T cell counts (cell/ml
blood)= 159.0622.7; CD8+ T cell counts: 164.0624.7). CD4+ and
CD8+ T cell counts from controls were in the reference range
(553.5653.9 and 724.4670.1 cells/ml blood, respectively).
Arginase activity is higher in PBMCs of VL patients
As shown in Figure 2, statistically significantly higher levels of
arginase activity were measured in PBMCs of VL patients as
Table 1. Clinical data.
Patient
(all male) Age (years) Spleen size (cm) Liver size (cm)
Parasite load
(Spleen)
Parasite load
(Bone marrow)
Duration of
Illness (weeks)
1 20 3 3 1+ 4
2 23 5 Not palpable 1+ 16
3 18 17 4 4+ 24
4 24 5 3 3+ 8
5 16 Not done Not done 4+ 12
6 30 7 3 3+ 4
7 20 12 3 1+ 24
8 28 11.5 Not palpable 3+ 4
9 25 8 Not palpable 2+ 4
10 20 5 Not palpable 3+ 2
11 18 15 4 4+ 4
12 25 7 3 2+ 16
13 18 12 5 4+ 12
14 38 11 4 5+ 12
15 24 6 3.5 2+ 12
16 19 8 Not palpable 4+ 3
17 22 5 Not palpable 4+ 4
18 20 5 Not palpable 1+ 4
19 32 4 5 3+ 8
20 22 13 6 3+ 12
21 18 Not palpable Not palpable 1+ 4
22 25 10 4 3+ 8
23 20 7 5 5+ 4
24 27 3 4 2+ 8
25 16 12 3 4+ 4
26 25 8 4 1+ 4
Spleen and liver size =measurement below left costal margin and right subcostal margin (respectively).
doi:10.1371/journal.pntd.0002134.t001
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compared to controls (patients: 106.6611.0, controls: 45.966.7 mU/
mg protein respectively, p=0.0045). Following 3–4 weeks of
treatment, these levels were considerably lower (treated patients:
64.865.3 mU/mg protein, p=0.0108). These results show that the
active phase of visceral leishmaniasis coincides with higher levels of
arginase activity in PBMCs.
CD15+ Arginase+ cells are more frequent among PBMCs
of VL patients
To determine the phenotype of arginase-producing cells, a
combination of extracellular (anti-CD14 and anti-CD15) and
intracellular (anti-arginase) markers was used [19]. The large
majority of arginase-expressing cells in PBMCs of patients express
CD15, a typical marker of neutrophils (14.9% of 15.1%=98.3%,
Figure 3A); the phenotype of arginase-expressing cells was similar
(CD142CD15+arginase+) in the PBMCs of controls and treated
patients (data not illustrated). The frequency of CD15+ cells
expressing arginase was .93.1% in all 17 patients and controls
tested (data not illustrated). Following density gradient purifica-
tion, neutrophils co-purify in the erythrocyte fraction and not with
the PBMCs. However, here we identify arginase-expressing
CD15+ cells in the PBMC fraction, this population will therefore
be referred to as low-density granulocytes (LDGs). The frequency
of LDGs was statistically significantly higher in the PBMCs of VL
patients as compared to controls (patients: 13.663.4, controls:
3.560.7, p=0.0001, Figure 3C). Following 3–4 weeks of
treatment, the frequency of LDGs was considerably lower (treated
patients: 4.161.3, p=0.0006). Similarly, the number of LDGs per
ml of blood was higher in patients as compared to controls and
treated patients (Table 3).
CD14+ cells of the large majority of patients (14 out of 17) did
not express arginase (the percentages of CD14+ arginase+ cells
were ,1%, Figure 3B), with only a small percentage of
CD14+arginase+ cells detected in the PBMCs of 3 patients
(1.7%, 3.5% and 2.8%, data not illustrated). The percentages of
CD14+ cells were lower during the active phase of the disease
(controls: 15.161.5 and patients: 7.861.2, p=0.0040), and did not
change significantly after 3–4 weeks of treatment (patients:
7.861.2 and treated patients: 15.762.7, p=0.1013)(Figure 4A).
Similar results were obtained with the number of CD14+ cells per
ml of blood (Table 3). The ratio of LDGs versus monocytes was
higher before treatment in VL patients (1.9760.63) as compared
to patients after 3–4 weeks of treatment (0.3460.12, p=0.0004)
and controls (0.1960.09, p,0.0001)(Figure 4B). Of note, the white
blood cell count per ml of blood was lower in patients before the
treatment as compared to controls and to treated patients
(Table 3).
Increased degranulation of LDGs in PBMCs of VL patients
Activation of neutrophils is accompanied by exocytosis of
arginase-containing azurophilic granules [23], which express
CD63. Release of these granules results in the incorporation of
CD63 into the membrane of neutrophils [24]. Therefore, we
measured the expression levels of CD63 and arginase in LDGs. As
shown in Figure 5A, CD63 MFI was statistically significantly
higher on LDGs isolated from the PBMCs of patients before
treatment as compared to controls (patients: 16.463.1, controls:
7.561.3, p=0.0066) and to treated patients (10.060.9,
p=0.0232), suggesting that the levels of degranulation are higher
in LDGs from patients before treatment. Since arginase has been
shown to be contained in the azurophilic granules found in the
cytoplasm of neutrophils, we assessed its MFI in LDGs: the lower
median values observed in the LDGs of VL patients did not reach
statistical significance (controls: 24.961.7 vs VL patients:
19.461.4, p=0.3126; VL patients: 19.461.4 vs treated patients:
23.461.0, p=0.0855). Next, we measured the levels of arginase
activity in the plasma and our results show that arginase activities
were statistically significantly higher in the plasma of patients
before treatment (23.964.8 mU/ml plasma) as compared to
controls (12.861.4 mU/ml plasma, p=0.0117) and treated
patients (13.961.1 mU/ml plasma, p=0.0168)(Figure 5C).
Lower levels of L-arginine in the plasma coincide with
downregulation of CD3f in CD4+ T cells
Since the results shown in Figure 5C show higher levels of
arginase activity in plasma from VL patients, we measured the
levels of L-arginine in the plasma. As shown in Figure 6A, a sharp
reduction in L-arginine levels was observed in the plasma of
patients before treatment (105.6612.4 mM) as compared to
healthy controls (179.0631.6 mM, p=0.0009); the increased
median levels of L-arginine did not reach statistical significance
in the plasma of patients after 3–4 weeks of treatment
(164.7619.8 mM, p=0.2934). It has been shown that decreased
Table 2. Haematological data.
Patients
Platelets
(6103)
White blood
cells (6103) Hct (%) Hb (g/dl)
1 190 4.6 38.4 12.1
2 14 1.2 25.9 7.8
3 134 1.9 24.7 7.4
4 38 0.8 23.8 7.2
5 Not done Not done Not done Not done
6 78 0.9 24.1 7.3
7 19 2.3 17.1 5.3
8 40 1 25.3 7.7
9 45 1.8 29.8 9.4
10 125 2.7 29.2 8.3
11 45 1.4 28.9 9
12 34 1 11.9 3.9
13 93 1.3 21.9 7
14 75 1.5 25.2 8.2
15 46 1.3 23.7 7
16 73 1.9 21.1 6.9
17 133 2.2 23 7.2
18 87 3 29 9.4
19 65 1.9 21.4 6.59
20 126 2 22.1 6.6
21 43 2 12.6 3.9
22 27 1.1 26.1 8
23 43 2.5 21.1 6.3
24 57 1 25.3 7.9
25 67 2.4 24 7
26 49 1.6 21.1 Not obtained
Median 57±8.6 1.8±0.2 24.0±1.1 7.3±0.3
Hct = hematocrit; Hb = haemoglobin.
Normal range: platelets (6103) = 150–450; white blood cells (6103) = 4.5–10.5;
Hct (%) = 35–60; hb (g/dl) = 11–18.
The white blood cells were counted in total blood before Ficoll using a
COULTER AcNT diff Hematology Analyzer and are expressed as number of WBC
(6103) per ml of blood.
doi:10.1371/journal.pntd.0002134.t002
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levels of L-arginine result in T cell suppression, as measured by
decreased expression of CD3f [17,19]. We next assessed the
expression levels of CD3f in CD4+ and CD8+ T cells in PBMCs:
statistically significantly lower CD3f MFI in CD4+ T cells from
patients before treatment (15.460.6) was observed as compared to
controls (20.061.3, p=0.0008); higher CD3fMFI in CD4+ T cells
that shows a trend towards significance was observed in the treated
patients (17.460.8, p=0.081)(Figure 6B). No statistical signifi-
cance was observed in CD3f MFI in CD8+ T cells (patients:
16.561.1, controls: 20.461.5, treated patients: 17.460.8,
Figure 6C).
Discussion
PBMCs from patients with active VL lose the ability to mount
an antigen-specific immune response, as shown by the inability of
their T cells to proliferate and produce IFN-c; this is however
reversed after successful chemotherapy (summarised in [12,13]).
Here we identified a novel mechanism in human visceral
leishmaniasis that might account for the poor T cell responses
associated with active visceral leishmaniasis. We show that the
activity of arginase, an enzyme that has been associated with
immunosuppression, is higher before treatment in PBMCs and
plasma of VL patients and decreases rapidly following successful
treatment. Indeed, our results show that as early as 3 weeks post
treatment, the levels of arginase are similar to those of controls.
Similarly, the frequency of arginase-expressing cells in the PBMCs
and their absolute counts were shown to be considerably greater
during active disease, indicating that increased arginase activity
Figure 1. BMI, upper arm circumference and CD4+ and CD8+ T cell counts. BMI (A) and circumference of the upper arm (B) were compared
in controls (n = 12) and patients (n = 25). CD4+ (C) and CD8+ T (D) cell counts in the blood of controls (n = 10) and patients (n = 25) were measured by
flow cytometry. Ethiopian national reference range for CD4+ T cells counts (cells/ml of blood) = 500–1300; Ethiopian national reference range for CD8+
T cells counts (cells/ml of blood) = 320–1800. Box = interquartile range and median; whiskers = range. Patients = VL patients before treatment.
doi:10.1371/journal.pntd.0002134.g001
Figure 2. Arginase activity in PBMCs. PBMCs were isolated by
density gradient from the blood of controls (n = 10), VL patients (n = 14)
and treated VL patients (n = 12) and the activity of arginase was
measured by enzymatic assay. Box = interquartile range and median;
whiskers = range. Statistical significance was determined by a two-tailed
Mann-Whitney test. NS = not significant. Patients = VL patients before
treatment; treated patients = VL patients after 3–4 weeks treatment.
doi:10.1371/journal.pntd.0002134.g002
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and increased frequency of arginase-expressing cells are hallmarks
of active visceral leishmaniasis. Further, we show that increased
arginase activity and frequency and absolute numbers of LDGs in
the blood of patients with active VL coincide with lower levels of
L-arginine in the plasma and lower expression levels of CD3f in
CD4+ T cells. We have previously shown that increased levels of
arginase activity correlated with disease severity in HIV seropos-
itive patients [21]. Here, no significant correlation was observed
between any of the clinical and haematological parameters or the
nutritional status (data not shown) and arginase activity or
frequency of LDGs. This is likely to be due to the fact that the
patients recruited in our study all presented with severe VL.
Therefore, our results suggest that arginase activity is significantly
increased in VL patients presenting with severe manifestations of
the disease.
We and others have already described LDGs [19,21,25,26];
following density gradient centrifugation, these cells co-purify with
PBMCs and not with the erythrocyte fraction, suggesting that they
are activated granulocytes [27], which have changed their density.
The degree of activation of neutrophils and degranulation depends
on the strength of the activating signal and increased activation
results in the release of granules in the following order: 1) secretory
granules; 2) gelatinous (tertiary) granules; 3) specific (secondary)
granules and 4) azurophilic (primary) granules. CD63 is found in
the membrane of azurophilic granules and we show here that the
MFI of CD63, whose upregulation parallels release of azurophilic
granule by activated neutrophils [24,28], is significantly higher on
LDGs from active VL patients. Whereas we have previously
shown that arginase is contained in azurophilic granules [23],
arginase has also been detected in gelatinous granules [29]. Since
azurophilic granules are the last granules to be released and since
CD63 is selectively upregulated on neutrophils following release of
azurophilic granules [24,28], in agreement with our previous
results [23], we can conclude that arginase-containing azurophilic
granules are released. And indeed, the levels of arginase activity
are higher in the plasma from patients during the active phase of
Figure 3. Phenotype and frequency of arginase-expressing cells in PBMCs. PBMCs were isolated by density gradient from the blood of
controls (n = 14), VL patients (n = 17) and treated VL patients (n = 12). The phenotype of arginase-expressing cells was determined by flow cytometry.
(A) Dot plot profile of CD15+ arginase+ cells, data show the results of one representative experiment out of 17 independent experiments; (B) dot plot
profile of CD14+ arginase+ cells, data show the results of one representative experiment out of 17 independent experiments. (C) Percentages of
CD15+arginase+ cells in the PBMCs of controls (n = 14), VL patients (n = 17) and treated VL patients (n = 12). Box = interquartile range and median;
whiskers = range. Statistical significance was determined by a two-tailed Mann-Whitney test. NS = not significant. Patients = VL patients before
treatment; treated patients = VL patients after 3–4 weeks treatment.
doi:10.1371/journal.pntd.0002134.g003
Table 3. Absolute numbers of LDGs, CD14+ cells and white
blood cells.
Controls Patients Treated patients
LDGs/ml blood 18.866.96103 28.767.66103 14.365.36103
CD14+ cells/ml blood 8.361.36104 1.360.76104 5.261.16104
White cells/ml blood 6.060.86105 1.760.56105 3.560.36105
The white blood cell counts were determined after Ficoll using trypan blue
exclusion and are expressed as cell number per ml of blood.
doi:10.1371/journal.pntd.0002134.t003
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the disease. These results suggest that LDGs have degranulated
and released their arginase. We have recently shown that a similar
population of LDGs is significantly increased in the blood of HIV
seropositive patients with low CD4+ T cell counts: this population
also expressed higher CD63 and lower arginase MFIs; in addition,
the levels of CD11b, CD15, CD33, CD66b, CD63 were
significantly higher and that of CD16 significantly lower as
compared to NDGs [30]. The majority of LDGs in HIV patients
Figure 4. Frequency of LDGs and monocytes in PBMCs. PBMCs were isolated by density gradient from the blood of controls (n = 14), VL
patients (n = 17) and treated VL patients (n = 12), (A) the frequencies of monocytes were determined by flow cytometry and (B) the ratio of low-
density granulocytes (LDGs) to monocytes was calculated by dividing the percentages of LDGs by the percentages of monocytes. Box = interquartile
range and median; whiskers = range. Statistical significance was determined by a two-tailed Mann-Whitney test. NS =not significant. Patients = VL
patients before treatment; treated patients = VL patients after 3–4 weeks treatment.
doi:10.1371/journal.pntd.0002134.g004
Figure 5. Phenotype of arginase expressing LDGs and arginase plasma levels. PBMCs were isolated by density gradient from the blood of
controls [n = 8 (A) and n= 13 (B)], VL patients [n = 10 (A) and n= 16 (B)] and treated VL patients [n = 8 (A) and n=12 (B)] and the mean fluorescence
intensity of CD63 (A) and arginase (B) in CD15+ cells was determined by flow cytometry. (C) Plasma was isolated by centrifugation of the blood of
controls (n = 21), VL patients (n = 21) and treated VL patients (n = 14) and the activity of arginase was measured by enzymatic assay. Box = interquartile
range and median; whiskers = range. Statistical significance was determined by a two-tailed Mann-Whitney test. NS =not significant. Patients = VL
patients before treatment; treated patients = VL patients after 3–4 weeks treatment.
doi:10.1371/journal.pntd.0002134.g005
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were mature segmented neutrophils [30]. However, the origins of
these cells as well as the factors resulting in the degranulation of
neutrophils during VL are still unclear. It is possible that during
VL, neutrophils are activated in the spleen and in the liver and
that a fraction of these activated neutrophils recirculate and are
therefore detected in the PBMCs (Figure 3). An extensive and
systemic activation of neutrophils would result in the release of
large amount of arginase, widespread depletion of L-arginine and
major disruption of many cellular and organ functions and is
therefore unlikely.
In contrast to our results, a recent study by Mukhopadhyay et al
showed that the levels of arginase in the plasma of VL patients in
India are not affected by treatment with sodium antimony
gluconate [31]. These discrepancies are likely to be due to the
different techniques used to measure arginase activity: in the
present study, we deducted the levels of urea present in the plasma
from the values obtained following activation of arginase. Of note,
even though our results suggest that LDGs have degranulated, we
cannot conclude from the present study that the increased arginase
we detect in the plasma of VL patients is coming from LDGs, as it
could also have been released from damaged hepatocytes. The
increased arginase activity in PBMCs and plasma coincides with
lower levels of L-arginine. We have previously shown that
increased arginase activity, a marker of disease severity in HIV+
patients, correlated with decreased levels of L-arginine [21].
Another study has also described a correlation between elevated
arginase activities and lower levels of L-arginine in patients with
pulmonary tuberculosis, that was reversed following successful
treatment [32]. In our study, in addition to the increased arginase
activity measured in the plasma of patients with active VL, it is
possible that malnutrition also impacted on the lower levels of L-
arginine. Out of 25 patients, 11 were malnourished and 12 were
severely malnourished. Since malnutrition results in reduced levels
of L-arginine in the plasma [33,34,35], it is likely that this has also
contributed to the lower levels of L-arginine in the plasma.
Further, since the patients do not get nutritional supplements
during treatment, malnutrition could also explain why the levels of
L-arginine do not increase after 3–4 weeks of treatment. We had a
limited number of patients in this study and our cohort of controls
consisted of 4 endemic controls and 10 members of the staff of the
hospital; we did not find significant differences between the
nutritional status of these 2 subgroups of control. It will be
interesting to compare the levels of L-arginine in the plasma of a
large cohort of controls coming from endemic areas and from
patients with active VL, to estimate the contribution of increased
arginase and/or protein-energy malnutrition to the lower levels of
L-arginine.
It has been shown previously that arginase-induced L-arginine
depletion results in impaired T cell responses (reviewed in
[14,15,16,36]. Our results suggest that during active VL, LDGs
release arginase and we speculate that arginase-induced L-arginine
depletion contributes to the poor antigen-specific T cell response
Figure 6. L-arginine levels and CD3f expression in CD4+ and CD8+ T cells. Plasma was isolated by centrifugation of the blood of controls
(n = 11), VL patients (n = 11) and treated VL patients (n = 11) and (A) the levels of L-arginine were measured by HPLC. PBMCs were isolated by density
gradient from the blood of controls (n = 10), VL patients (n = 10) and treated VL patients (n = 10) and the mean fluorescence intensity of CD3f was
determined in CD4+ T cells (B) and CD8+ T cells (C). Box = interquartile range and median; whiskers = range. Statistical significance was determined by
a two-tailed Mann-Whitney test. NS = not significant. Patients = VL patients before treatment; treated patients = VL patients after 3–4 weeks
treatment.
doi:10.1371/journal.pntd.0002134.g006
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that is an immunological hallmark of active VL; it is also possible
that this mechanism negatively impacts on the capacity of immune
cells to respond to other antigens and might therefore account for
the frequent opportunistic infections observed in VL patients.
The impaired Leishmania-specific T cell responses observed
during active VL is reversed in cured patients ([6] and reviewed in
[12,13]). Our results show that CD3f MFI are significantly lower
in CD4+ T cells, but not in CD8+ T cells, and 3–4 weeks post
treatment, the increased median in CD3f in both cell type were
not significantly different. It is possible that this lack of significance
in CD3f in CD8+ T cells might be due to the limited number of
patients recruited in this study. We have previously shown that
CD4+ and CD8+ T cells both display decreased CD3f expression
levels and this coincides with increased arginase activity [37]. The
differences in L-arginine levels in the plasma were not statistically
significant either; it is possible that this is due to the fact that the
blood was collected only after 3–4 weeks of treatment.
The observation that PBMCs from patients with active VL
mount a poor antigen-specific response is in apparent contradic-
tion with recent studies, which show a clear production of IFN-c
using a whole blood assay [38,39]: the authors of these studies
have suggested that during the density gradient centrifugation used
to isolate PBMCs, factors important for the production of IFN-c
might be removed. Our results obtained in a separate study show
that heparin has a remarkable effect on the survival of LDGs.
Indeed, our results show a dramatic decrease in the frequencies of
LDGs when the blood was collected into sodium heparin as
compared to EDTA: we compared the frequency of CD15+
arginase+ cells in the blood of 5 patients, collected in sodium
heparin or EDTA and observed an average of 75.56617.26% less
CD15+arginase+ cells in blood collected in heparin compared to
EDTA (% of LDGs in blood collected on EDTA=2.4860.96 vs
0.5960.55 for blood collected with heparin (n = 5), p.0.05) [40].
Since in the above-mentioned studies [38,39], blood was collected
into heparin, it is possible that the resulting low frequency of LDGs
was not sufficient to suppress the production of IFN-c. Notably,
neutrophils are extremely difficult to freeze and indeed, we were
not able to freeze LDGs: we froze the PBMCs of 8 patients in FCS
containing 10% DMSO, and following careful thawing of the cells,
we observe an average reduction of 97.364.9% in the frequency
of CD15+arginase+ cells. Similar results were recently published
[41], where it was shown that the frequency of CD15+ cells in
PBMCs was significantly reduced after cryopreservation. Since we
did not have the facilities to perform stimulation assays with
PBMCs from VL patients and since it is not possible to
cryopreserve LDGs to send them in another laboratory with
adequate facilities, we were therefore not able to directly
demonstrate that LDGs have the ability to suppress T cell
responses.
We have shown in an experimental model of cutaneous
leishmaniasis that increased arginase activity is highest at the site
of pathology, and significantly lower in the draining lymph nodes
[17]. Further, we have recently performed a study with patients
with localised cutaneous leishmaniasis and have shown that
consistent with the mouse model, arginase activity is increased in
the lesions, but not in the periphery [37]. Therefore, it is possible
that the higher frequencies of LDGs we observed in the PBMCs of
VL patients before treatment are only a weak reflection of the
events occurring at the local sites of Leishmania replication, such as
spleen, liver or lymph nodes; and that considerably stronger T cell
suppression is likely to occur in these sites. Indeed, a recent study
showed in a mouse model of prostate-specific inflammation, that a
population of Gr-1+ CD11b+ arginase+ cells isolated from the site
of inflammation are more suppressive than those isolated from the
periphery [42]. Further studies will be essential in assessing the
strength of LDG-mediated T cell suppression in different
compartments and to show whether arginase-mediated L-arginine
metabolism is a key element in the outcome of VL.
We and others have shown that Leishmania parasites express
their own arginase [43,44,45]. However, it is highly unlikely that
parasite arginase accounts for the arginase we detect in the
PBMCs and in the plasma as it is very difficult to detect parasite in
the blood of VL patients [46].
In summary, here we show that high arginase activity in PBMCs
is a marker of active visceral leishmaniasis and we propose that
arginase-induced L-arginine depletion contributes to disease
severity in these patients.
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